Form 4: Neurocrine Biosciences' Chief Medical Officer, Eiry Roberts, Reports Stock Transactions

Eiry Roberts, Chief Medical Officer of Neurocrine Biosciences, reports the vesting of restricted stock units and subsequent sale of shares under a pre-arranged trading plan.

Summary

• Eiry Roberts, the Chief Medical Officer of Neurocrine Biosciences, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On January 31, 2025, 2,769 restricted stock units (RSUs) vested, each representing a contingent right to receive one share of Neurocrine Biosciences' common stock.
• Simultaneously, Dr. Roberts sold 1,457 shares of common stock at a weighted average price of $152.8045 per share, with individual sales prices ranging from $151.94 to $153.31.
• The sale was executed under a Rule 10b5-1 trading plan adopted on September 1, 2022.
• Following these transactions, Dr. Roberts directly owns 32,373 shares and indirectly owns 31,188 shares through The Stephen Taylor and Eiry W. Roberts Joint Trust Agreement.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing reflects routine transactions under a pre-arranged trading plan, with no indication of positive or negative implications for the company's performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and potential future performance.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the relatively small volume of shares sold.

Key Dates

Keywords

Form 4, Neurocrine Biosciences, NBIX, Eiry Roberts, Chief Medical Officer, Stock Sale, Restricted Stock Units, RSU, 10b5-1 Trading Plan, Beneficial Ownership